Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADPT Adaptive Biotechnologies	$11.06 -4.2%	$10.30	$3.85 ▼ $12.43	$1.75B	1.83	1.63 million shs	1.59 million shs
OXBDF Oxford BioMedica	$4.77	$4.32	$3.15 ▼ $5.68	$505.44M	1.11	601 shs	N/A
SRPT Sarepta Therapeutics	$18.21 -5.3%	$29.52	$16.88 ▼ $153.30	$1.89B	0.45	2.26 million shs	4.08 million shs
TARS Tarsus Pharmaceuticals	$40.58 -2.3%	$42.12	$20.08 ▼ $57.28	$1.74B	0.8	686,104 shs	538,928 shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADPT Adaptive Biotechnologies	-4.24%	-5.79%	+7.17%	+47.66%	+174.44%
OXBDF Oxford BioMedica	0.00%	+2.58%	+2.36%	+51.43%	+7.55%
SRPT Sarepta Therapeutics	-5.30%	-4.31%	-49.67%	-66.24%	-88.07%
TARS Tarsus Pharmaceuticals	-2.29%	+2.24%	-0.76%	-17.84%	+44.93%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADPT Adaptive Biotechnologies	2.8494 of 5 stars	1.4	1.0	0.0	4.2	3.1	2.5	0.6
OXBDF Oxford BioMedica	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SRPT Sarepta Therapeutics	4.7294 of 5 stars	4.2	2.0	0.0	4.2	2.9	1.7	1.9
TARS Tarsus Pharmaceuticals	1.832 of 5 stars	3.5	0.0	0.0	0.0	2.6	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADPT Adaptive Biotechnologies	2.86	Moderate Buy	$10.57	-4.42% Downside
OXBDF Oxford BioMedica	0.00	N/A	N/A	N/A
SRPT Sarepta Therapeutics	2.44	Hold	$58.54	221.48% Upside
TARS Tarsus Pharmaceuticals	3.00	Buy	$66.67	64.28% Upside

Current Analyst Ratings Breakdown

Latest OXBDF, ADPT, SRPT, and TARS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/10/2025	SRPT Sarepta Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$30.00 ➝ $28.00
6/25/2025	SRPT Sarepta Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Sell
6/20/2025	SRPT Sarepta Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$123.00 ➝ $45.00
6/20/2025	SRPT Sarepta Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform
6/18/2025	ADPT Adaptive Biotechnologies	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$15.00
6/18/2025	SRPT Sarepta Therapeutics	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$85.00 ➝ $40.00
6/18/2025	SRPT Sarepta Therapeutics	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$24.00
6/17/2025	SRPT Sarepta Therapeutics	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Hold ➝ Hold	$50.00 ➝ $25.00
6/17/2025	SRPT Sarepta Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold	$29.00
6/17/2025	SRPT Sarepta Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$60.00 ➝ $30.00
6/17/2025	SRPT Sarepta Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$100.00 ➝ $75.00

(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADPT Adaptive Biotechnologies	$189.53M	8.87	N/A	N/A	$1.37 per share	8.07
OXBDF Oxford BioMedica	$111.34M	4.54	N/A	N/A	$1.01 per share	4.72
SRPT Sarepta Therapeutics	$1.90B	0.94	$2.31 per share	7.89	$15.99 per share	1.14
TARS Tarsus Pharmaceuticals	$182.95M	9.32	N/A	N/A	$5.87 per share	6.91

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADPT Adaptive Biotechnologies	-$159.49M	-$0.96	N/A	N/A	N/A	-74.84%	-62.79%	-24.55%	7/30/2025 (Estimated)
OXBDF Oxford BioMedica	-$195.90M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
SRPT Sarepta Therapeutics	$235.24M	-$2.69	N/A	1.66	N/A	-11.12%	-14.88%	-5.12%	8/6/2025 (Estimated)
TARS Tarsus Pharmaceuticals	-$115.55M	-$2.73	N/A	N/A	N/A	-44.91%	-39.72%	-25.74%	8/6/2025 (Estimated)

Latest OXBDF, ADPT, SRPT, and TARS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	ADPT Adaptive Biotechnologies	-$0.24	N/A	N/A	N/A	N/A	N/A
8/6/2025	Q2 2025	SRPT Sarepta Therapeutics	$0.89	N/A	N/A	N/A	$530.66 million	N/A
8/6/2025	Q2 2025	TARS Tarsus Pharmaceuticals	-$0.41	N/A	N/A	N/A	$95.81 million	N/A
5/6/2025	Q1 2025	SRPT Sarepta Therapeutics	$2.20	-$3.42	-$5.62	-$4.60	$685.75 million	$744.86 million
5/1/2025	Q1 2025	ADPT Adaptive Biotechnologies	-$0.28	-$0.20	+$0.08	-$0.20	$42.13 million	$52.44 million
5/1/2025	Q1 2025	TARS Tarsus Pharmaceuticals	-$0.69	-$0.64	+$0.05	-$0.64	$72.50 million	$78.34 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADPT Adaptive Biotechnologies	N/A	N/A	N/A	N/A	N/A
OXBDF Oxford BioMedica	N/A	N/A	N/A	N/A	N/A
SRPT Sarepta Therapeutics	N/A	N/A	N/A	N/A	N/A
TARS Tarsus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADPT Adaptive Biotechnologies	N/A	2.92	2.82
OXBDF Oxford BioMedica	N/A	N/A	N/A
SRPT Sarepta Therapeutics	1.00	4.02	2.46
TARS Tarsus Pharmaceuticals	0.21	5.57	5.54

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADPT Adaptive Biotechnologies	99.17%
OXBDF Oxford BioMedica	N/A
SRPT Sarepta Therapeutics	86.68%
TARS Tarsus Pharmaceuticals	90.01%

Insider Ownership

Company	Insider Ownership
ADPT Adaptive Biotechnologies	6.40%
OXBDF Oxford BioMedica	N/A
SRPT Sarepta Therapeutics	7.70%
TARS Tarsus Pharmaceuticals	8.97%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADPT Adaptive Biotechnologies	790	151.92 million	142.19 million	Optionable
OXBDF Oxford BioMedica	891	105.96 million	N/A	Not Optionable
SRPT Sarepta Therapeutics	1,372	98.28 million	90.71 million	Optionable
TARS Tarsus Pharmaceuticals	50	42.01 million	38.25 million	Optionable

OXBDF, ADPT, SRPT, and TARS Headlines

Recent News About These Companies

William Blair Issues Pessimistic Estimate for TARS Earnings

3 hours ago | marketbeat.com

William Blair Has Bearish Estimate for TARS FY2026 Earnings

July 16 at 2:01 AM | americanbankingnews.com

What is William Blair's Estimate for TARS FY2026 Earnings?

July 15 at 8:23 AM | marketbeat.com

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Receives $66.67 Consensus PT from Analysts

July 15 at 2:17 AM | americanbankingnews.com

Tarsus Pharmaceuticals Stock Price, Quotes and Forecasts

July 13 at 10:38 PM | benzinga.com

Hot Tick Summer Is Here. Here’s What You Need to Know and How to Stay Safe

July 12, 2025 | gizmodo.comG

Grant GrossMendelsohn LLC Sells 26,143 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

July 12, 2025 | marketbeat.com

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Given Average Recommendation of "Buy" by Analysts

July 12, 2025 | marketbeat.com

Allspring Global Investments Holdings LLC Sells 12,401 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

July 5, 2025 | marketbeat.com

Tarsus Pharmaceuticals Inc Ordinary Shares - Morningstar

July 2, 2025 | morningstar.comM

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shares Sold by Lisanti Capital Growth LLC

June 29, 2025 | marketbeat.com

Tarsus Pharmaceuticals Becomes Oversold (TARS)

June 19, 2025 | nasdaq.com

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shares Bought by GAMMA Investing LLC

June 19, 2025 | marketbeat.com

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Given Average Recommendation of "Buy" by Brokerages

June 17, 2025 | marketbeat.com

Tarsus Pharmaceuticals CCO sells $765,800 in stock

June 13, 2025 | investing.com

Tarsus Pharmaceuticals CCO sells $765,800 in stock

June 13, 2025 | investing.com

Stocks Showing Improving Market Leadership: Tarsus Pharmaceuticals Earns 87 RS Rating

June 6, 2025 | msn.com

Tarsus Pharmaceuticals assumed with an Outperform at Oppenheimer

June 2, 2025 | msn.com

Tarsus to Participate in Upcoming Investor Conferences

May 29, 2025 | globenewswire.com

Tarsus Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)

May 27, 2025 | benzinga.com

Tarsus Pharmaceuticals at H.C. Wainwright: Expanding Horizons with Xdemvy

May 21, 2025 | investing.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

OXBDF, ADPT, SRPT, and TARS Company Descriptions

Adaptive Biotechnologies NASDAQ:ADPT

$11.06 -0.49 (-4.24%)

Closing price 07/15/2025 04:00 PM Eastern

Extended Trading

$11.12 +0.05 (+0.50%)

As of 08:23 AM Eastern

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

Oxford BioMedica OTCMKTS:OXBDF

$4.77 0.00 (0.00%)

As of 07/11/2025

Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its s LentiVector platform technology is an advanced lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems. The company operates in two segments, Platform and Product. The Platform segment engages in bioprocessing and process development activities for third parties. The Product segment is involved in the research and development of new gene therapeutic product candidates. The company collaborates with pharmaceutical and biotechnology companies providing viral vector development and manufacturing services in lentivirus, adeno-associated virus, and adenoviral vectors. The company was formerly known as Pinco 838 Limited and changed its name to Oxford Biomedica plc in October 1996. Oxford Biomedica plc was incorporated in 1996 and is headquartered in Oxford, the United Kingdom.

Sarepta Therapeutics NASDAQ:SRPT

$18.21 -1.02 (-5.30%)

Closing price 07/15/2025 04:00 PM Eastern

Extended Trading

$18.44 +0.23 (+1.26%)

As of 08:27 AM Eastern

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Tarsus Pharmaceuticals NASDAQ:TARS

$40.58 -0.95 (-2.29%)

Closing price 07/15/2025 04:00 PM Eastern

Extended Trading

$40.58 +0.01 (+0.01%)

As of 07/15/2025 04:04 PM Eastern

Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time